Comparison of Cervical Ultrasound and Echoscintigraphy for Preoperative Localization Diagnosis in Primary Hyperparathyroidism
Overview
The biological diagnosis of the primary hyperparathyroidism is now facilitated by the reliability of the balance of phosphate and calcium and the dosage of parathyroid hormone (PTH). This diagnosis of preoperative localization is important as surgery are now targeted to the responsible lesion. The "gold standard" for this localization is the cervical ultrasound exploring the usual sites of adenomas and a MIBI scintigraphy (the parathyroid adenoma significantly concentrating this cell marker). However, the diagnosis of preoperative localization remains a subject of discussion as to the most appropriate tests. Indeed, the morphological diagnosis is performed at the ultrasound stage in more than half the cases. It is the new performance of this morphological examination that makes it possible to obtain these results.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Diagnostic
- Masking: None (Open Label)
- Study Primary Completion Date: October 5, 2019
Interventions
- Other: cervical ultrasound
- cervical ultrasound will be realized by a endocinologist trained in the cervical ultrasound
Arms, Groups and Cohorts
- Experimental: Patients
Clinical Trial Outcome Measures
Primary Measures
- Adenoma parathyroid diagnosed using cervical ultrasound
- Time Frame: Day 0
- Adenoma parathyroid diagnosed using cervical ultrasound. Cervical ultrasound will be realized by a endocrinologist trained in the cervical ultrasound and not informed of the results of the echoscintigraphy
- Adenoma parathyroid diagnosed using echoscintigraphy
- Time Frame: Day 0
- Adenoma parathyroid diagnosed using echoscintigraphy. Echoscintigraphy will be realized by a nuclear physician not informed of the results of the cervical ultrasound
- Adenoma parathyroid diagnosed using anatomopathology
- Time Frame: Day 0
- Adenoma parathyroid diagnosed by anatomopathologist, after surgery.
Participating in This Clinical Trial
Inclusion Criteria
- Patients with primary hyperparathyroidism with surgery indication – Age > 18yo Exclusion Criteria:
- surgical contraindication – medical treatment by cinacalcet – non sporadic hyperparathyroidism – Age <18yo – Protected by the law
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- CHU de Reims
- Provider of Information About this Clinical Study
- Sponsor
- Overall Contact(s)
- Brigitte DELEMER, 0326788101, bdelemer@chu-reims.fr
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.